Jeremy Yuen Chun Teoh

Dr. Jeremy Yuen Chun Teoh

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2023 in Nature Reviews Disease Primers
Verified
Journal Article
Closed access
PDF file
LDLars Dyrskjøt
Lars Dyrskjøt
DHDonna E. Hansel
Donna E. Hansel
JEJason A. Efstathiou
Jason A. Efstathiou
MKMargaret A. Knowles
Margaret A. Knowles
MGMatthew D. Galsky
Matthew D. Galsky
DTDan Theodorescu
Dan Theodorescu

31 March 2022 in Nature Reviews Urology
Verified
Journal Article
Closed access
PDF file
Jeremy Yuen Chun TeohJeremy Yuen Chun Teoh
Jeremy Yuen Chun Teoh
Ashish M. KamatAshish M. Kamat
Ashish M. Kamat
PBPeter C. Black
Peter C. Black
PGPetros Grivas
Petros Grivas
SSShahrokh F. Shariat
Shahrokh F. Shariat
MBMarek Babjuk
Marek Babjuk

1 August 2020 in European Urology
Verified
Journal Article
Closed access
Jeremy Yuen Chun TeohJeremy Yuen Chun Teoh
Jeremy Yuen Chun Teoh
WOWilliam Lay Keat Ong
William Lay Keat Ong
DGDaniel Antonio González-Padilla
Daniel Antonio González-Padilla
DCDaniele Castellani
Daniele Castellani
JDJustin M. Dubin
Justin M. Dubin
SLStacy Loeb
Stacy Loeb

1 January 2022 in European Urology Focus
Verified
Journal Article
Closed access
Junjie HuangJunjie Huang
Junjie Huang
DLDavid Leung
David Leung
ECErica On-Ting Chan
Erica On-Ting Chan
VLVeeleah Lok
Veeleah Lok
SLSophia Leung
Sophia Leung
Martin WongMartin Wong
Martin Wong


24 October 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Jeremy Yuen Chun TeohJeremy Yuen Chun Teoh
Jeremy Yuen Chun Teoh
HHHoyee W Hirai
Hoyee W Hirai
JHJason M W Ho
Jason M W Ho
FCFelix C H Chan
Felix C H Chan
KTKelvin Tsoi
Kelvin Tsoi
CNChi-Fai, Anthony Ng
Chi-Fai, Anthony Ng
To investigate the global incidence of prostate cancer with special attention to the changing age structures. Data regarding the cancer incidence and population statistics were retrieved from the International Agency for Research on Cancer in World Health Organization. Eight developing and developed jurisdictions in Asia and the Western countries were selected for global comparison. Time series were constructed based on the cancer incidence rates from 1988 to 2007. The incidence rate of the population aged ≥ 65 was adjusted by the increasing proportion of elderly population, and was defined as the “aging-adjusted incidence rate”. Cancer incidence and population were then projected to 2030. The aging-adjusted incidence rates of prostate cancer in Asia (Hong Kong, Japan and China) and the developing Western countries (Costa Rica and Croatia) had increased progressively with time. In the developed Western countries (the United States, the United Kingdom and Sweden), we observed initial increases in the aging-adjusted incidence rates of prostate cancer, which then gradually plateaued and even decreased with time. Projections showed that the aging-adjusted incidence rates of prostate cancer in Asia and the developing Western countries were expected to increase in much larger extents than the developed Western countries.